Dr. Wang Zhulun, Chief Scientific Officer of the company, has more than 25 years of R&D experience in the biomedicine and pharmaceutical industries. He has led over and facilitated the IND applications of more than 10 small molecules and large molecule therapeutic drugs in many start-up companies and large enterprises. Including multiple marketed products and drugs under development, its research covers multiple therapeutic areas such as oncology, neuroscience, metabolic disorders, and inflammatory/autoimmune diseases. She received her bachelor’s degree from the university of Science and Technology of China, received his PhD from the State University of New York and received postdoctoral training at the University of Texas.